Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A New Regime Takes The Reins At Teva

Executive Summary

New CEO Kare Schultz has established a new leadership team and structure at the generic drug giant, as head of R&D Michael Hayden, Global Specialty Medicines CEO Rob Koremans and Global Generics Medicines CEO Dipankar Bhattacharjee will all leave at the end of the year.

You may also be interested in...

Teva CEO Schultz Walks Smack Into A Rough Financial Situation

Teva announced lower third quarter sales, said it would miss it's 2017 profit forecasts and acknowledged looming debt challenges. It was only CEO Kare Schultz's second day on the job.

Teva Appoints New Global Generics Head Amid Massive Integration

Just months after Teva closed the $40.5bn acquisition of Allergan Generics, the company said the man expected to lead the integration, Siggi Olafsson, will step down and be succeeded by Dipankar Bhattacharjee.

Teva In Transition: Generics, Specialty And 'The Space Between'

In an interview with Scrip's sister publication "The Pink Sheet", President of Global R&D Michael Hayden talked about integrating Allergan generics, Teva's late-stage specialty pipeline and its 17 new therapeutic entities, medicines that bridge generics and specialty medicine.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts